Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk

Popular weight-loss drugs have boosted Novo Nordisk and Eli Lilly. After huge gains, the drugmakers' stocks now face this risk.

Top Weight-Loss Rivals Share This Risk After Eye-Popping Runs

Eli Lilly has more work it wants to do with the hard-won success from its weight loss and diabetes drugs, Zepbound and Mounjaro, outgoing CFO Anat Ashkenazi told CNBC. The company is working to ramp up manufacturing, expand patient access to the treatments and change long-held misconceptions about obesity.

How Eli Lilly is managing soaring demand for GLP-1s, according to outgoing CFO Anat Ashkenazi

Amazon

Broadcom

Alphabet

Tesla

Visa

The first company to reach a $4 trillion stock market valuation may not even be on your radar screen now. While almost everyone expects one of the three largest U.S. companies — Microsoft MSFT, +0.22%, Apple AAPL, -0.82% and Nvidia NVDA, +1.75% as of June 14 — to be the first to hit that milestone, it isn't necessarily a given.

8 stocks other than Microsoft, Apple and Nvidia that could be worth $4 trillion in three years

Madrigal Pharmaceuticals

Madrigal Pharmaceuticals is the only company with an approved drug for MASH. Eli Lilly's latest clinical trial data shows that its candidate may perform even better.

Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word.

Eli Lilly is developing Mounjaro (tirzepatide) for treating non-alcoholic steatohepatitis. The drugmaker reported positive phase 2 results along those lines earlier this year.

Mounjaro Is Targeting Another Multibillion-Dollar Market: Is Eli Lilly Stock a Buy?

Eli Lilly's potential Alzheimer's treatment looks closer than ever to approval. It could be a nice addition to the pharmaceutical giant's already-deep portfolio.

Eli Lilly Scores Another Major Win and Lines Up Its Next Blockbuster

IonQ

Lucid Group

Understanding when to sell a particular stock might be as important in investing as when to acquire it. Here, the focus is on identifying stocks to sell during market downturns, as it is crucial to mitigate potential financial risks when investing.

Exit Alert: 3 Stocks to Offload Before the Downturn

If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.

Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)

The pharmaceutical sector is one that has gone from decades of heavy investment, high growth, and consolidation to a maturing space with a few key players that have more recently provided much more stagnant growth than investors who were around in past decades may remember.

10 Reasons to Buy Eli Lilly Stock Now

Eli Lilly has one obesity drug that's already competing against Wegovy, with more drugs potentially on the way. Novo Nordisk could have a more powerful obesity drug than Wegovy waiting in the wings.

Wegovy's Precarious Position: 3 Drugs Most Likely to Dethrone Novo Nordisk's Blockbuster Obesity Drug

JPMorgan Chase & Co

Exxon Mobil

Far from being a source of concern, the U.S. stock market's extremely low volatility is something to celebrate. The CBOE Volatility Index VIX, or VIX, which is a measure of the S&P 500's SPX expected volatility over the subsequent month, is now lower than 88% of daily readings since 1990.

These 4 S&P 500 stocks are helping to tame U.S. market volatility

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Eli Lilly (LLY) is a Top Momentum Stock for the Long-Term

Apple

Fidelity Blue Chip Growth ETF

General Motors

Coca-Cola

Marvell Technology

Microsoft

Netflix

NVIDIA

Snap

T Rowe Price Blue Chip Growth ETF

Uber

UnitedHealth Group

Both Fidelity and T. Rowe Price ETFs are both cashing in on "blue chips.

Fidelity And T. Rowe Price Score Big On These 'New' Blue Chips

Amgen

Ozempic and Wegovy (semaglutide for diabetes and weight loss, respectively) are popular weight-loss drugs that have taken the world by storm. Indeed, the craze is showing no signs of slowing down as more supply of GLP-1 receptor agonists comes online to meet blistering demand.

3 Stocks to Buy as Ozempic Surges in Popularity

You won't want to miss out on the stock Warren Buffett has been scooping up. A healthcare leader is poised to capture the lion's share of a potential $130 billion weight loss market.

Want to Get Richer? 2 Top Stocks to Buy Now and Hold Forever.

CrowdStrike

Gap Inc

UiPath

Shopify

Target

It remains a tale of two markets. Some stocks have wind in their sails and are soaring to all-time highs.

4 Best Stocks to Buy and 3 Best Stocks to Sell: June 2024

Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab

Revenue from Eli Lilly's weight-loss drug is expected to triple over the next five years to over $50 billion. The views have driven Eli Lilly stock to a record.

Eli Lilly Runs Up 49% With Expectations For Weight-Loss Sales To Triple

Johnson & Johnson

Sanofi

Artificial intelligence is forecast to drive an innovation bonanza in healthcare. This innovation boom is expected to increase the human lifespan dramatically.

A Life Expansion Revolution Is Coming: 3 Stocks That Could Lead the Charge

Eli Lilly's revenue has taken off thanks to two of its drugs that doctors prescribe for weight loss. The company also has a full portfolio of other products, and some increased revenue in the double digits in the latest quarter.

Is Eli Lilly the Best Pharmaceutical Stock for You?

Continually confident about Eli Lilly because of the enormous success of its weight loss and diabetes drugs, CNBC's Jim Cramer said the company's new Alzheimer's treatment has the potential to further boost business. On Monday, a panel of advisors to the Food and Drug Administration unanimously recommended the drug, currently known as donanemab.

Jim Cramer says Eli Lilly isn't a 'one trick pony' after FDA advisers endorse its Alzheimer's drug

Eli Lilly and Company has gained approval on yet another prospective blockbuster drug, Donanemab, the second FDA-approved Alzheimer's treatment on the market. It is too soon to know what kind of impact Lilly's Donanemab will have on future earnings, but I predict it will be fairly positive. Eli Lilly has proven its commitment to product depth and innovation, one of the many reasons it's the largest holding at my firm.

Eli Lilly Continues To Climb As Alzheimer's Drug Gains FDA Approval

BofA Securities analyst Geoff Meacham reiterated the Buy rating on Eli Lilly And Company LLY, with a price forecast of $1,000.

Eli Lilly's Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst

Eli Lilly's stock has seen significant gains due to the success of its GLP-1 franchise and the potential of donanemab for Alzheimer's disease. The FDA's Advisory Committee endorsed donanemab for Alzheimer's treatment, but concerns remain post-approval requirements. Though competition in the Alzheimer's market is limited, sales projections for anti-amyloid antibodies may be overhyped.

Eli Lilly: The Road To Approval Of Donanemab Is Open

24/7 Wall Street Insights Unlike the declining stocks of some of its pharmaceutical rivals, Eli Lilly has continually beat analysts' forecasts and prospered accordingly.

News for Eli Lilly Stock (LLY)